R. Giro´n et al. / Life Sciences 71 (2002) 1023–1034
1033
less than fentanyl and a duration of action similar to that of fentanyl. Its pharmacological profile suggests
that it is a very potent and selective A opioid agonist. This, together with previous results from our group
[10], suggests that substitution of the phenyl ring of fentanyl by a 1-phenylpyrazole rest is a good
alternative for preparing new fentanyl analogs with selective interaction with A receptors and potent
antinociceptive effect. Evaluation of side effects of these new compounds is currently under study.
Acknowledgements
This work was supported by Spanish government grants SAF 97-0044-CO2 and SAF 00-0114-C02,
and Laboratorios del Dr. Esteve, S.A.
References
[1] Janssen PAJ. Review of the chemical features associated with strong morphine-like activity. British Journal of Anaesthesia
1962;34:260–8.
[2] Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain
control. Drugs 1997;53:109–38.
[3] Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clinical Pharmacokinetics 1983;8:422–46.
[4] Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer drugs 1995;3:39–43.
[5] Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through
human cadaver skin. Pharmaceutical Research 1989;6(10):825–32.
[6] Bagley JR, Kidzma LV, Lalinde NL, Colapret JA, Huang BS, Lin BS, Jerussi TP, Benvenga MJ, Doorley BM, Ossipov
MH, Spaulding TC, Spencer HK. Evolution of the 4-anilidopiperidine class of opioid analgesics. Medicinal Research
Reviews 1991;71:403–36.
[7] Llama EF, Del Campo C, Capo M. New heteroaryl derivatives of fentanyl. Journal of Pharmacy and Pharmacology
1991;43:68–9.
[8] Bi-Yi C, Wen-Qiao J, Jie C, Xin-Jian C, You-Cheng Z, Zhi-Qiang C. Analgesic activity and selectivity of isothiocyanate
derivatives of fentanyl analogs for opioid receptors. Life Sciences 1999;65:1589–95.
ˇ
[9] Micovıc IV, Ivanovic MD, Vuckovic SM, Prostran MS, Dosen-Micovic L, Kiricojevic VD. The synthesis and preliminary
´
ˇ
pharmacological evaluation of 4-methyl fentanyl. Bioorganic and Medicinal Chemistry Letters 2000;10:2011–4.
´
´
[10] Jagerovic N, Cano C, Elguero J, Goya P, Callado LF, Meana JJ, Giron R, Abalo R, Ruiz D, Goicoechea C, Martın MI.
Long-acting fentanyl analogs: synthesis and pharmacology of N-(1-phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidinyl)
propanamides. Bioorganic Mededicinal Chemistry [in press].
[11] Essawi MYH. Fentanyl analogues with a modified propanamido group as potential affinity labels: synthesis and in vivo
activity. Pharmazie 1999;54(4):307–8.
[12] Janssen PJA. N-(1-Aralkyl-4-piperidyl)alkanoic acid anilides, U.S. Patent 3141 823, 1964. Chemical Abstracts 1964;
62:14634c.
[13] Borsch RF, Bernstein MD, Durst HD. The cyanohydridoborate as a selective reducing agent. Journal of the American
Chemical Society 1971;93:2897–903.
[14] Ambache N. Separation of the longitudinal muscle of the rabbit’s ileum as a broad sheet. Journal of Physiology (London)
1954;125:53P–5P.
[15] Oka T, Negishi K, Suda M, Matsumiya T, Inazy T, Masaaki U. Rabbit vas deferens: a specific bioassay for opioid n-
receptor agonists. European Journal of Pharmacology 1980;73:235–6.
[16] Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides
from the brain with potent opiate agonist activity. Nature 1975;258:577–9.
[17] Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-
opioid receptor antagonists. Life Sciences 1987;40:1287–92.